Ewan Craig McNay - US grants

[unreadable] DESCRIPTION (provided by applicant): The long-term goals of this proposal are, first, to develop understanding of how insulin acts on the brain - specifically, the hippocampus - to modulate cognitive processes; second, to determine how systemic insulin resistance, as seen in type 2 diabetes (T2DM), affects insulin's actions on the brain. We aim to build on our preliminary data to establish the physiological role of insulin within the hippocampus. Research in our laboratory has shown that insulin enhances cognitive performance in rats when given directly to the hippocampus, a brain region densely populated with insulin receptors and GluT4 (insulin- sensitive) glucose transporters. Our preliminary data suggest that this enhancement is accompanied by modulation of local brain metabolism. However, the mechanism(s) by which insulin acts within the hippocampus remain to be determined. The fact that insulin acts to enhance cognitive processes is of particular interest when taken together with reports of cognitive impairment accompanying diabetes, and in particular deficits in memory. Moreover, T2DM has recently been shown to markedly increase the risk of dementia, and to be associated with alterations of central beta-amyloid processing, a key marker for Alzheimer's disease. We hypothesize that the systemic insulin resistance seen in T2DM is accompanied by reduced central sensitivity within the hippocampus, which contributes to the cognitive impairment found in diabetic patients. Our initial data suggest that, indeed, a rodent model of T2DM shows impaired cognitive function accompanied by impaired responsiveness to hippocampal insulin administration and impaired hippocampal amyloid processing. LAY LANGUAGE: Insulin has recently been identified as having actions within the brain, as well as on skeletal muscle and fat. We seek to understand how insulin acts to modulate cognitive processes, particularly within the hippocampus - a key brain region for learning and memory - and, critically, how dysregulation of insulin contributes to (i) the cognitive dysfunction seen in Type 2 diabetes, and (ii) the increased risk of developing Alzheimer's disease found in such patients. [unreadable] [unreadable] [unreadable]

? DESCRIPTION (provided by applicant): The goal of this proposal is to prevent and treat the cognitive and neural impairment associated with impaired brain insulin signaling. Such signaling is now recognized as central to the impact of both type 2 diabetes (T2DM) and Alzheimer's disease (AD), which is now commonly characterized as 'type 3 diabetes' [1, 2]. Work in our lab, funded by the grant of which this is a renewal, showed that insulin is a key component of hippocampal metabolism and memory processes and that systemic insulin resistance impairs both hippocampal metabolism and cognitive function [3-6]. However, little is known about the molecular mechanism(s) by which insulin regulates cognitive and neural processes. Similarly, the clinical fact that T2DM causes cognitive impairment is well-established, but not understood at a cellular or molecular level. Several clinical studies have shown a clear link between T2DM and development of AD [7-16]; conversely, AD patients show reduced hippocampal insulin signaling that accompanies hypometabolism and abnormal accumulation of beta-amyloid (A?). Several in vitro studies suggested that insulin and A? oppose each other at a molecular level [17-24]; recent in vivo work from our lab showed that administration of oligomeric A? to the hippocampus caused rapid cognitive impairment, reduced glucose metabolism, and impaired translocation of the insulin-regulated glucose transporter GluT4 [6]: this closely resembles hippocampal insulin resistance. Further, our animal model of diet-induced T2DM causes elevation of hippocampal amyloid [25]: a key hypothesis presented here is that this causes T2DM-associated cognitive impairment as well as the elevated risk of dementia. Understanding insulin's modulation of hippocampal processes, and how this modulation is impaired by insulin resistance and/or A?, is central to developing treatment for T2DM and/or AD. Long-term, the public health goal of this work is to identify therapeutic targets for prevention and treatment of brain dysfunction in T2DM and AD. The experiments proposed here build on the successful progress during this grant's first funding period. We will determine the molecular effectors by which insulin, and conversely insulin-resistance, impact hippocampal function. As part of this, we will directly manipulate candidate effectors, supported by preliminary data, including GluT4 and multiple forms of A?. The second aim, again emerging from strong preliminary data, is to investigate the different involvement of insulin and downstream effectors in distinct stages of hippocampal memory processing.